Predictions
Sio Gene Therapies Inc.
Start price
Target price
Perf. (%)
€1.87
05.11.20
05.11.20
€2.00
05.11.21
05.11.21
-7.97%
06.11.21
06.11.21
Future proof or reliable business model
Applied DNA Sciences Inc.
Start price
Target price
Perf. (%)
€5.90
05.11.20
05.11.20
€20.00
05.11.21
05.11.21
-17.29%
06.11.21
06.11.21
Market Leader or Top 3
Could be very worthwhile Investment >20% year
Very Future proof/growth oriented business model
Aphria Inc.
Start price
Target price
Perf. (%)
€4.70
05.11.20
05.11.20
-
05.11.21
05.11.21
170.32%
06.11.21
06.11.21
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Delivery Hero SE
Start price
Target price
Perf. (%)
€112.60
05.11.20
05.11.20
€120.00
2.98%
16.12.20
16.12.20
Could be worthwhile Investment >10% per year
Market Leader or Top 3
Well known brand
Very Future proof/growth oriented business model
EOG Resources Inc.
Start price
Target price
Perf. (%)
€30.40
05.11.20
05.11.20
-
05.11.21
05.11.21
57.24%
09.01.21
09.01.21
High dividend yield expected
Sustainability is little important
Higher risks for its business
Significant cyclical dependencies
Cadence Design Systems
Start price
Target price
Perf. (%)
€103.62
05.11.20
05.11.20
€150.00
05.11.21
05.11.21
48.54%
06.11.21
06.11.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
ROE higher than 15% per year
ProSiebenSat.1 Media SE
Start price
Target price
Perf. (%)
€9.99
04.11.20
04.11.20
-
27.08%
25.11.20
25.11.20
Risky Investment
Jumia Technologies AG
Start price
Target price
Perf. (%)
€15.20
04.11.20
04.11.20
€49.00
04.11.21
04.11.21
59.87%
19.04.21
19.04.21
Good rating
Standard Investments for future growth
High valuation
Very low/no dividend yield expected
Washington Prime Group Inc.
Start price
Target price
Perf. (%)
€4.76
04.11.20
04.11.20
€6.30
04.11.21
04.11.21
-11.41%
06.11.20
06.11.20
Differentiated customer and product portfolio
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Fair valuation
CytoDyn Inc_INT
Start price
Target price
Perf. (%)
€2.26
04.11.20
04.11.20
€3.20
04.11.21
04.11.21
-43.45%
10.07.21
10.07.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Significant cyclical dependencies
Schaeffler AG
Start price
Target price
Perf. (%)
€5.55
04.11.20
04.11.20
€7.90
04.11.21
04.11.21
25.95%
05.11.21
05.11.21
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Splunk Inc.
Start price
Target price
Perf. (%)
€177.72
04.11.20
04.11.20
€189.00
04.11.21
04.11.21
-29.12%
10.12.20
10.12.20
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Expedia Inc.
Start price
Target price
Perf. (%)
€84.12
04.11.20
04.11.20
€159.00
04.11.21
04.11.21
82.48%
05.11.21
05.11.21
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Good rating
Nidec Corp.
Start price
Target price
Perf. (%)
€90.84
04.11.20
04.11.20
€100.00
4.10%
09.11.20
09.11.20
Future proof or reliable business model
WAVE Life Sciences Ltd
Start price
Target price
Perf. (%)
€6.40
04.11.20
04.11.20
-
-9.38%
07.11.20
07.11.20
Could be very worthwhile Investment >20% year
Bio-Gate AG
Start price
Target price
Perf. (%)
€5.90
04.11.20
04.11.20
-
04.11.21
04.11.21
-32.20%
05.11.21
05.11.21
Growths faster than the competition
Few uniques
Dependend from some customers or products
Probably not worthwhile Investment
American International Group Inc.
Start price
Target price
Perf. (%)
€27.87
04.11.20
04.11.20
-
04.11.21
04.11.21
20.65%
07.01.21
07.01.21
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Paychex Inc.
Start price
Target price
Perf. (%)
€73.88
04.11.20
04.11.20
-
04.11.21
04.11.21
1.96%
11.01.21
11.01.21
High dividend yield expected
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
BYD Co. Ltd
Start price
Target price
Perf. (%)
€19.21
04.11.20
04.11.20
€25.00
04.11.21
04.11.21
78.65%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Fair valuation
NIO Inc. ADR
Start price
Target price
Perf. (%)
€31.30
04.11.20
04.11.20
€40.00
04.11.21
04.11.21
10.86%
05.11.20
05.11.20
Innovative
EBIT growth >5% per year expected
Top 10 in its market
Known brand
BioLine RX Ltd ADR
Start price
Target price
Perf. (%)
€2.46
03.11.20
03.11.20
€3.50
04.11.21
04.11.21
-4.88%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
DuPont de Nemours Inc.
Start price
Target price
Perf. (%)
€50.84
03.11.20
03.11.20
€25.00
04.11.21
04.11.21
2.68%
10.11.20
10.11.20
DBV Technologies S.A.
Start price
Target price
Perf. (%)
€3.45
03.11.20
03.11.20
-
04.11.21
04.11.21
136.51%
15.01.21
15.01.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group